Evaluation of the autologous bone marrow mononuclear therapy and functional restoration in the scarred myocardium by imaging analysis by Gokhale, Alla Gopala Krishna et al.
133 Journal of Cardiovascular Disease Research Vol. 2 / No 2
ABSTRACT
A 62-year-old male patient with previous history of myocardial infarction, akinetic myocardial segments, and 
an ejection fraction of 31% with the NYHA class III category was selected for the autologous bone marrow 
(ABM)-derived mononuclear cell fraction injection during CABG surgery. Nitrate augmented myocardial 
tracer uptake was imaged by ECG gated SPECT pre- and 1 year post-ABM therapy, using radiotracer Tc99m 
Sestamibi. The baseline gated SPECT demonstrated full thickness infarct in 40% area of LAD territory. Bone 
marrow aspirate of 20.0 ml from sternum yielding a mono nuclear cell fraction of 4.5 × 107 cells/ml was 
suspended in 2.0 ml of sterile normal saline to be injected at eight sites of the injured myocardium. There were 
no apparent side effects due to the procedure, i.e., life threatening events, major bleeds, reaction, or shock. 
The case was followed at the end of 1, 3, 6 months by ECG and Holter monitor and ECG gated SPECT at the 
end of 12 months. The gated SPECT images demonstrated mild but definitely improved tracer uptake within 
part of the infarcted segments along with improvement in ejection fraction to 45%, and a clinical change in 
the NYHA Class to II. Cell-based therapy may offer benefits of induction of normal tissue microenvironment.
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INTRODUCTION
Cardiac remodeling using adult stem cell therapy in clinical 
trials of post-myocardial infarction (MI) injury, as the 
therapeutic strategy during cardiac surgery is entering 
clinical practice.[1] The experimental and clinical models in 
various studies have yielded equivocal results. At present, 
this treatment is highly promising to become a standard 
treatment due to its effectiveness. The variables are 
confounding in these studies. It is yet to be determined the 
appropriate cell dosing, cell type, timing of the therapy, 
choice of cases, and the degree of stem cell approach 
for treating these otherwise nonamenable to therapeutic 
option cases.[2] Here we report adult stem cell therapy for 
myocardial revascularization and repair during CABG 
surgery. It is also important to determine objectively 
the functional improvement in these cases due to stem/
progenitor cell therapy alone. Molecular imaging is rapidly 
taking the center stage in determining the effects of the 
stem cell therapy in vivo and the long-term follow-up.[3] 
Molecular imaging itself is currently evolving with focus 
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on the multimodal approach for addressing the issues of 
stem cell homing, proliferation, and differentiation.[4] It 
has been, therefore, aimed at, to assess the improvement 
in the LV function and the global ejection fraction, using 
autologous bone marrow mononuclear fraction as an 
adjunct to CABG surgery, using noninvasive molecular 
imaging, 2D Echo along with the changes in the NYHA 
class changes in a case of scarred myocardium due to 
severe myocardial infarction.
MATERIALS AND METHODS
The study has been IRB/IEC approved. High risk video 
consent was obtained. The case has been recruited 
into the study which is registered with ICMR with 
universal trial number: TEMP UTRN 042233121-
1506201022763720. 
Screening procedures
The case was screened at the baseline for the extent of 
scarred myocardium using ECG gated SPECT imaging 
of myocardium after rest injection of Tc99m Sestamibi 
augmented with sublingual nitrate preparation. NYHA 
class was determined based on the questionnaire of 
NYHA and was classified under category III. The cardiac 
MRI and SPECT images were addressed at the baseline 
and the ejection fraction was estimated along with the 
2D-echocardiogram. Akinetic and dyskinetic segments 
were assessed.
Bone marrow aspiration
Bone marrow (20.0 ml) from sternum during coronary 
bypass surgery (CABG) from 62-year-old male was 
aspirated under general anesthesia (GA).
Mononuclear fraction isolation
The bone marrow was equally diluted with normal saline, 
and the mononuclear fraction was isolated using the clinical 
grade Ficoll gradient and centrifugation method (Sigma, 
USA). The cells were counted in a coulter counter and 
viability was checked using the trypan blue dye exclusion 
method. The sample was assessed for CD34+/CD45+ cells 
(0.7%) using FACS Calibur prior to dispatch of cells to the 
theater before the completion of the CABG surgery. The 
cells thus isolated were suspended in 2.0 ml of normal saline.
Stem cell therapy
The cell suspension was injected circumferentially at eight 
sites of 0.1 ml volume of cell suspension each in this case, 
surrounding the scarred myocardium.
Follow-up
The case was followed up periodically at 1, 3, 6 months 
using ECG, Holter monitor and ECG gated SPECT at the 
end of 1 year. The parameters assessed included the global 
ejection fraction, increased perfusion using SPECT image 
analysis, end-diastolic volume (EDV), end-systolic volume 
Figure 1: Nitrate augmented myocardial tracer uptake was imaged by ECG gated SPECT using radiotracer Tc99m Sestamibi which revealed 
full thickness infarct in 40% area of LAD territory. At the end of 1-year period, improved tracer uptake could be demonstrated by SPECT within 
part of the infracted segments along with improvement in ejection fraction to 45%.135 Journal of Cardiovascular Disease Research Vol. 2 / No 2
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(ESV), echocardiography and changes in the NYHA class 
category and angina status.
RESULTS
A 62-year-old male patient with previous history of 
myocardial infarction, akinetic myocardial segments and 
an ejection fraction of <31% with the NYHA class III 
category was selected for the autologous bone marrow-
derived mononuclear cell fraction injection during CABG 
surgery. Myocardial SPECT demonstrated full thickness 
infarct in 40% area of LAD territory. Bone marrow aspirate 
(20.0 ml) from sternum has yielded a mono nuclear cell 
fraction of 4.50 × 107 cells/ml with a positive 0.7% of 
CD45+/CD34+ cells. The cells were suspended in 2.0 
ml of sterile normal saline to be injected at eight sites of 
the injured myocardium. There were no apparent side 
effects due to the procedure, i.e., life threatening events, 
major bleeds, reaction or shock. The case was followed 
at the end of 1, 3, 6 and 12 months. At the end of 1 year 
period, improved tracer uptake could be demonstrated 
by SPECT within part of the infarcted segments along 
with improvement in ejection fraction to 45% and clinical 
change in the NYHA Class to II [Figure 1].
Ejection fraction improved from 31% to 45% as 
demonstrated by the % gated SPECT analysis of the 
hemodynamic data. LV end-diastolic volume per ml was 
184 ml prior to the therapy followed by 208 ml post-1 
year. Stroke volume index improved from 33 ml/m2 to 
50 ml/ m2. Similarly, LV end-systolic volume was 127 
ml prior and 120 ml post-therapy. The infarct region as 
severe perfusion defect measured as % area under LAD 
territory has shown an improvement from 40% to 30%. 
The NYHA class demonstrated changes from Class III 
to Class II [Table 1].
DISCUSSION
The crucial issues that need consideration, while using 
stem cell therapy as a treatment option either as standalone 
therapy or synergistic in nature, are the cell type, cell 
number, therapeutic time window, route of delivery and 
critical evaluation of therapeutic benefit.[5-8] As reported by 
the Strauer et al., it is thought that the use of bone marrow 
mononuclear fraction would include the hematopoietic and 
nonhematopoietic cells that would be actively harnessing 
the tissue microenvironment to a desired protection 
level.[9] The preclinical models have demonstrated that 
hematopoietic fraction could differentiate to lineages 
that could regenerate the damaged tissue due to   
in vivo differentiation to cardiomyocytes using host niche 
(microenvironment).[10] The nonhematopoietic component 
owing to its immunomodulatory properties and release 
of trophic factors is assumed that it could induce the 
remodeling of the injured myocardium in a synergistic 
way to accelerate the repair process and regenerate a viable 
tissue and thereby increase the LV function.[11] There are 
preclinical reports suggesting the route of delivery as other 
important criteria for the accessibility of the stem cells. It 
was observed that the i.v. infusion of stem cells would be 
of little value as they would primarily go to liver, spleen 
and the residual fraction reaching the injured myocardium 
may not be adequate and hence, the controversial results 
of lack of improvement in some studies. other studies 
have demonstrated good results using combination of 
routes, i.e., intracoronary and intramyocardial for the 
maximum homing of cells for tissue repair.[12] However, 
other studies did not corroborate similar findings owing 
to complex variables and confounding factors. In order 
to maximize the availability of viable cell to the scarred 
tissue, direct small volume injections at number of sites 
surrounding the injured myocardium was administered 
to the case under discussion. Reports from Lunde and 
Aakhus indicated the long-term improvement in acute 
myocardial infarction (AMI) using intracoronary mBMC 
treatment.[13] The optimum cell dose for the stem treatment 
is yet to be determined. However, the dose that we 
adopted in this case was as per our previous publication,   
where the improvement of LV function was dose-
dependent.[14] Meluzín et al. reported that mBMC 
transplants demonstrate regional myocardial function 
of the infarcted wall in a dose-dependent manner.[15] In 
an another study of dilated cardiomyopathy, our results 
corroborated with the group on the improved ejection 
fraction with increased CD34+/CD45+ cells.[15] Dose-
dependent improvement is a significant observation 
from different groups necessitating a need to arrive 
at an algorithm based on variable factors. And a large 
Table 1: Cardiac function analysis at 1 year follow-up
Parameter Before cell 
therapy
One year after 
cell therapy
Hemodynamic data
LV ejection fraction,% by  
gated SPECT
Stroke volume index, ml/m2
31
33
45
50
Cardiac geometry
LV end-diastolic volume, ml 
LV end-systolic volume, ml
184
127
208
120
Infarct region as severe 
perfusion defect (i.e., <30%  
of maximal activity) measured 
as % area under LAD
40% 30%
NYHA classification Class III Class II
Hemodynamic parameters and cardiac geometry have demonstrated improvement in 
the global ejection fraction from 31% to 45% by the % gated SPECT analysis. The 
infarct region as severe perfusion defect measured as % area under LAD territory 
has shown an improvement from 40% to 30%. The NYHA class demonstrated 
changes from Class III to Class II.136 Journal of Cardiovascular Disease Research Vol. 2 / No 2
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cohort of the sample size from all over world can alone 
circumvent the dose criteria. The current follow-up criteria 
from each study group thus far have singularly focused 
on the functional improvement. With the availability of 
noninvasive technology, it is now possible to address 
the structural stratification vis-à-vis the functional 
improvement.[16,17] The reported case has significantly 
demonstrated the increased perfusion and the improved 
viable myocardium on the rest MPI gated SPECT images 
due to stem cells although it may be argued that CABG 
is responsible for the LV function improvement. The 
gated SPECT images demonstrate the nitrate augmented 
myocardial tracer uptake using radiotracer Tc99m Sestamibi 
which revealed improved tracer uptake within part of the 
infarcted segments along with improvement in ejection 
fraction to 45%. It is pertinent to the stem cell therapy 
to optimize the therapeutic window time as this may 
limit the performance of the cells in the acute stage with 
inflammatory responses and the implications thereafter in 
the AMI.[18] With the advances in the imaging technology, 
it is important to address the stem cell tracking for its 
homing, proliferation, and differentiation potential to be 
able to provide tangible solution to the critical factors and 
the benefit of the stem cell therapy in modern medicine.
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